1. Home
  2. ACHR vs GPCR Comparison

ACHR vs GPCR Comparison

Compare ACHR & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Archer Aviation Inc.

ACHR

Archer Aviation Inc.

HOLD

Current Price

$6.61

Market Cap

4.5B

Sector

Industrials

ML Signal

HOLD

Logo Structure Therapeutics Inc.

GPCR

Structure Therapeutics Inc.

HOLD

Current Price

$54.51

Market Cap

3.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACHR
GPCR
Founded
2018
2016
Country
United States
United States
Employees
N/A
233
Industry
Aerospace
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
4.5B
3.8B
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
ACHR
GPCR
Price
$6.61
$54.51
Analyst Decision
Buy
Strong Buy
Analyst Count
6
12
Target Price
$12.00
$103.17
AVG Volume (30 Days)
41.0M
516.8K
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
30.28
N/A
EPS
N/A
N/A
Revenue
$300,000.00
N/A
Revenue This Year
$4,986.67
N/A
Revenue Next Year
$876.87
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.30
$18.26
52 Week High
$14.62
$94.90

Technical Indicators

Market Signals
Indicator
ACHR
GPCR
Relative Strength Index (RSI) 62.29 61.77
Support Level $6.49 $43.76
Resistance Level $7.40 $57.15
Average True Range (ATR) 0.50 2.39
MACD 0.21 0.43
Stochastic Oscillator 73.58 93.26

Price Performance

Historical Comparison
ACHR
GPCR

About ACHR Archer Aviation Inc.

Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner. The company is building a platform to deliver aircraft, technologies, and services to customers world-wide across commercial and defense sectors.

About GPCR Structure Therapeutics Inc.

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.

Share on Social Networks: